Oncology Central

Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?


Melanoma incidence is rapidly increasing in the geriatric population making it a major public health issue [1,2]. Healthcare cost analysis of cancer treatment suggests a significant economic burden related to metastatic melanoma treatment of the elderly patient [3]. Larger studies have shown that age is an independent negative prognostic factor of survival in older subjects diagnosed with cutaneous melanoma [4]. Melanoma is an immunogenic tumor and anti-melanoma immunity plays an important role in shaping its course as well as the rising incidence noted in the geriatric population [5].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.